An observational study in Infertility, sponsored by Tang-Du Hospital. Recruiting at 1 site in China. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Tang-Du Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Infertility with a site in China — 38 open to participants now, 41 under way, 5 of them phase 3. Infertility · China.
Among the 139 studies in Infertility with a site in China, this one is the 22nd largest by planned enrollment of the 32 observational ones that give a count, is one of 14 that started in 2025, is one of 32 observational ones, reaches primary completion later than 23 of the 40 other live ones, and was the 132nd registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →38 of the 139 studies in Infertility with a site in China are open now. Recruiting first, the newest first:
Peking University People's Hospital · Sites in China
Ages 20–40 · Women only
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 36–39 · Women only
Li Li · Sites in China
Ages 18–45 · Women only · Healthy volunteers
Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Sites in China
Ages 20–40 · Women only
Li-jun Ding · Sites in China
Ages 18–39 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 20 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 15 · Phase 4 14
First in 2003; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 200 across 592 observational studies indexed under Infertility.
Median enrollment 248 across the 107 interventional studies, 550 across the 32 observational. Of the 56 that completed or were terminated, 4 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 139 have an industry lead sponsor. The 10 most frequent:
Tang-Du Hospital is the lead sponsor of 167 studies on the registry; 78 are open to participants now.
Tang-Du Hospital has 2 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
12 of the studies in Infertility with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT07696351Li-jun DingUltra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis | 2026-12-31 |
| NCT07050537The First Affiliated Hospital with Nanjing Medical UniversityA Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology | 2027-03-31 |
| NCT07533630Reproductive & Genetic Hospital of CITIC-XiangyaProspective International Multi-center Clinical Trial of PGT-A Upgrade | 2027-06 |
Add all 12 to your calendar (.ics) → With an account.
Among the 139 studies in Infertility with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this prospective observational cohort study is to evaluate the effect of routine clinical anticoagulant therapy on endometrial receptivity and subsequent pregnancy outcomes in women with infertility. Researchers will utilize an ultrasound multimodal system to systematically assess endometrial parameters, including thickness, morphology, peristalsis, and blood flow indices. The study aims to enroll approximately 300 infertile women aged 20 to 45 years. Participants will be observed and grouped based on whether they receive anticoagulant medications, such as aspirin or heparin sodium, as part of their standard clinical care. The study will track ultrasound-based receptivity indicators and follow up on pregnancy status and outcomes at 45 and 90 days of gestation. This study is purely observational, and all clinical treatment decisions are made independently of the study protocol.
Background and Rationale:
Endometrial receptivity plays a pivotal role in the success of embryo implantation for patients with infertility. Impaired endometrial perfusion is considered a significant contributing factor to implantation failure. In routine clinical practice, anticoagulant therapies, such as low-dose aspirin and low molecular weight heparin (e.g., heparin sodium), are frequently utilized to improve local hemodynamics and endometrial receptivity. However, a systematic, non-invasive, and quantitative evaluation of these therapeutic effects on the endometrium is still required.
Multimodal ultrasound provides a comprehensive, real-time, and non-invasive approach to assessing endometrial dynamics. By integrating conventional 2D ultrasound, 3D ultrasound, and Doppler imaging, this technology can meticulously quantify endometrial parameters, offering valuable predictive insights for clinical pregnancy outcomes.
Study Design and Methodology:
This is a single-center, prospective, observational cohort study. The objective is to evaluate the impact of routine anticoagulant therapy on endometrial receptivity and subsequent pregnancy outcomes in infertile women using an ultrasound multimodal system.
The study plans to enroll approximately 300 eligible infertile women aged 20 to 45 years. Participants will be categorized into two observational cohorts based solely on their routine clinical care plans:
Observation Group: Patients receiving anticoagulant therapy (e.g., aspirin, heparin sodium) in addition to conventional treatment.
Control/Comparison Group: Patients receiving conventional treatment only. Note: The decision to administer anticoagulant therapy is entirely at the discretion of the attending physicians based on clinical indications, independent of this study protocol. This study is strictly observational and involves no protocol-driven interventions.
Data Collection and Assessments:
During the clinically defined window of implantation, all participants will undergo comprehensive multimodal ultrasound examinations. The primary ultrasonographic parameters to be recorded include:
Endometrial thickness and morphological patterns.
Endometrial peristalsis characteristics.
Endometrial and subendometrial blood flow indices, including Vascularization Index (VI), Flow Index (FI), and Vascularization Flow Index (VFI) via 3D power Doppler.
Follow-up and Endpoints:
Following the ultrasound assessments and embryo transfer/conception, participants will be longitudinally followed. The clinical endpoints, specifically the pregnancy status and outcomes, will be rigorously tracked and documented at 45 days and 90 days of gestation. The collected data will be analyzed to determine the correlation between the multimodal ultrasound parameters of endometrial receptivity under anticoagulant therapy and the ultimate pregnancy success rates.
The study population consists of adult female patients, aged 20 to 45 years, who have been clinically diagnosed with infertility. These patients are seeking routine infertility treatments, such as in vitro fertilization (IVF) and embryo transfer or monitored conception cycles, at Tangdu Hospital. The population includes patients who receive standard conventional treatment as well as those who are prescribed adjunctive anticoagulant therapy based on their routine clinical care indications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinically diagnosed with infertility and planning to undergo embryo transfer or monitored conception cycles.
Patients who have complete baseline clinical data and are willing to undergo multimodal ultrasound evaluation of endometrial receptivity during the window of implantation.
Voluntarily agreed to participate in this observational study and signed the form for data collection.
Exclusion Criteria:
Presence of untreated severe intrauterine lesions, such as submucosal fibroids, severe intrauterine adhesions, or endometrial polyps that may mechanically interfere with implantation.
Severe underlying systemic diseases, including but not limited to severe liver or kidney dysfunction, or malignant tumors.
Known severe bleeding disorders or strict to anticoagulant medications (for patients in the routine clinical care setting).
Patients who are unable to cooperate with the transvaginal multimodal ultrasound examination or complete the required follow-up for pregnancy outcomes.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this cohort receive routine clinical anticoagulant therapies (such as low-dose aspirin or low molecular weight heparin) in addition to their conventional infertility treatment. The use of anticoagulants is determined by the attending physician based on standard clinical indications, strictly independent of this observational study protocol.
Drug: Routine Anticoagulant Therapy (Aspirin or Heparin Sodium)
Patients in this cohort receive conventional infertility treatment only, without the addition of anticoagulant therapies, as per standard clinical practice.
Patients receive low-dose aspirin or low molecular weight heparin (e.g., heparin sodium) purely as part of their standard clinical care. The decision to initiate, adjust, or terminate this therapy is made entirely by the attending physician based on clinical indications, strictly independent of this observational study protocol. This is tracked solely as an observational exposure.
Clinical Pregnancy Rate
The clinical pregnancy rate is defined as the proportion of patients with the presence of at least one intrauterine gestational sac with a visible fetal heartbeat, confirmed by transvaginal ultrasound.
Time frame: Up to 90 days of gestation
Endometrial Thickness
The maximum anteroposterior diameter of the endometrium measured in millimeters (mm) in the midsagittal plane using 2D transvaginal ultrasound.
Time frame: During the window of implantation (prior to embryo transfer)
Endometrial Morphological Pattern
Evaluated via 2D transvaginal ultrasound and classified into three typical patterns: Type A (triple-line pattern), Type B (intermediate isoechogenic pattern), and Type C (homogeneous hyperechogenic pattern) to assess morphological receptivity.
Time frame: During the window of implantation (prior to embryo transfer)
Endometrial and Subendometrial Blood Flow Indices
Quantitative assessment of local tissue perfusion using 3D power Doppler ultrasound. The parameters measured include Vascularization Index (VI, reflecting vessel density), Flow Index (FI, reflecting blood flow intensity), and Vascularization Flow Index (VFI, a combination of vascularity and flow intensity).
Time frame: During the window of implantation (prior to embryo transfer)
Endometrial Peristalsis Frequency
The frequency of endometrial wave-like activity (contractions per minute) observed via continuous transvaginal ultrasound scanning for a duration of 3 to 5 minutes.
Time frame: During the window of implantation (prior to embryo transfer)
Early Miscarriage Rate
The proportion of patients who experience a spontaneous pregnancy loss after the initial ultrasound confirmation of an intrauterine clinical pregnancy, prior to 90 days of gestation.
Time frame: Up to 90 days of gestation
Plan to share: Yes — De-identified individual participant data (IPD) underlying the results reported in the published article will be shared. Data will be available to researchers who provide a methodologically sound proposal, purely for the purpose of achieving the aims in the approved proposal.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data will be available beginning 6 months and ending 36 months following article publication.
Access criteria: To gain access, data requestors will need to contact the corresponding author and sign a formal data access agreement.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Nov 2027, 26 months after the start.
Of 209 non-industry observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 100. This study's planned 26 months is below that.
Counting every sponsor, half of 240 studies reached it within 39 months; a quarter within 16 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.